Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Transplant Cell Ther. 2023 Jul 22;29(11):709.e1–709.e11. doi: 10.1016/j.jtct.2023.07.013

Figure 2:

Figure 2:

Long-term outcomes in adult allogeneic HCT survivors with AML, ALL, CML, and MDS who had survived in remission ≥1 year in remission by neighborhood poverty level: (A) Overall survival, (B) Relapse, and (C) Non-relapse mortality